Oramed Pharmaceuticals Inc. (TLV:ORMP)

Oramed Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY	FY
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Aug 31, 2021	Aug 31, 2020
Revenue	-	-	1.34	2.7	2.7	2.71
Revenue Growth (YoY)	-	-	-50.42%	-	-0.26%	0.26%
Gross Profit	-	-	1.34	2.7	2.7	2.71
Selling, General & Admin	7.17	6.46	8.14	15.66	-5.94	-4.23
Research & Development	5.85	6.32	8.97	27.64	-20.99	-10.24
Operating Income	-12.76	-12.78	-15.77	-40.6	24.22	11.76
Interest Income	2.67	-2.29	22.89	2.93	1.24	0.69
Interest Expense	-	-0.85	-2.04	-	-0.01	-0.44
Total Non-Operating Income (Expense)	2.67	-3.14	20.86	2.93	1.23	0.25
Pretax Income	-10.09	-15.92	5.09	-37.66	22.99	12
Provision for Income Taxes	-11.94	-3.18	-	-0.1	-	-
Net Income	-0.22	-38.16	10.61	-74.33	45.23	23.02
Minority Interest in Earnings	-0.04	-0.04	-0.44	-1.2	0.75	-
Net Income to Common	-0.22	-38.16	10.61	-74.33	45.23	23.02
Net Income Growth	-	-	-	-	96.45%	60.38%
Shares Outstanding (Basic)	41	41	40	39	28	21
Shares Outstanding (Diluted)	42	41	41	39	28	21
Shares Change (YoY)	1.03%	0.65%	4.02%	36.98%	38.66%	17.63%
EPS (Basic)	1.03	-0.48	0.14	-0.94	-0.78	-0.56
EPS (Diluted)	0.99	-0.48	0.14	-0.94	-0.78	-0.56
EPS Growth	800.00%	-	-	-	-	-
Free Cash Flow	-11.58	-8.43	-10.55	-28.41	-21.56	-12.52
Free Cash Flow Per Share	-0.28	-0.21	-0.26	-0.73	-0.76	-0.61
Gross Margin	-	-	100.00%	100.00%	100.00%	100.00%
Operating Margin	-	-	-1176.79%	-1501.96%	896.15%	433.84%
Profit Margin	-	-	379.70%	-1397.11%	850.50%	424.76%
FCF Margin	-	-	-787.24%	-1051.20%	-797.48%	-462.07%
EBITDA	-10.21	-12.59	-15.57	-40.54	24.3	11.76
EBITDA Margin	-	-	-1162.16%	-1499.82%	899.00%	434.10%
EBIT	-12.76	-12.78	-15.77	-40.6	24.22	11.76
EBIT Margin	-	-	-1176.79%	-1501.96%	896.15%	433.84%
Effective Tax Rate	147.91%	19.99%	0.00%	0.27%	0.00%	0.00%

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.